Understand the source comparison
Growth Hormone Pathway: CJC-1295 DAC vs Unmodified Analogs
CJC-1295 with Drug Affinity Complex (DAC) is a synthetic GHRH analog engineered with a maleimide-linked albumin-binding moiety. This modification extends its plasma half-life from 7 minutes (native GHRH) to approximately 6–8 days. The DAC modification allows C
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 with Drug Affinity Complex (DAC) is a synthetic GHRH analog engineered with a maleimide-linked albumin-binding moiety. This modification extends its plasma half-life from 7 minutes (native GHRH) to approximately 6–8 days. The DAC modification allows CJC-1295 to sustain pulsatile GH secretion across multiple ultradian cycles rather than producing a single acute spike, which more closely mirrors physiological GH release patterns in younger males. A Phase I trial conducted at McGill University found CJC-1295 DAC produced mean GH elevations of 2–10 times baseline that persisted for 9–11 days post-injection, with corresponding IGF-1 increases of 1.5–3× baseline sustained for 6 days.
- The primary andropause application: age-related GH deficiency compounds testosterone decline because GH and testosterone synergistically drive protein synthesis, lipolysis, and bone mineral density maintenance. Men over 50 exhibit 14% average reduction in GH secretion per decade. Independent of testosterone levels. Which accelerates sarcopenia and visceral adiposity even when TRT is administered. CJC-1295 DAC is used in research models to determine whether restoring sustained GH pulsatility can reverse anabolic resistance in aging muscle tissue. The unmodified version (CJC-1295 without DAC, also called Modified GRF 1-29) requires daily dosing and produces shorter-duration GH elevations, making it less practical for multi-week andropause studies where sustained anabolic signaling is the target.
- One caveat most protocols overlook: CJC-1295 DAC's extended half-life means receptor desensitisation becomes a real risk if dosing frequency isn't properly spaced. Pituitary GHRH receptors downregulate under continuous agonist exposure. Studies using twice-weekly CJC-1295 DAC showed diminishing GH response by week 8, whereas once-weekly dosing maintained consistent GH output across 12 weeks. At Real Peptides, we've found researchers achieve more reproducible results with 7-day dosing intervals and 4-week observation windows than with higher-frequency protocols.